Physician profile

Kyle King

Dentist · Lufkin, TX

NPI 1528444007

$3,021.27

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$1,092.87
Education$926.04
Food and Beverage$473.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ultradent Products INC $1,092.87 2023 Opalescence
Patterson Companies, INC. $896.65 2021-2024
Dentsply Sirona INC $539.19 2019-2024 Protaper Gold Conform Fit
Straumann USA LLC $175.00 2020
Pulpdent Corporation $141.70 2022
Nobel Biocare USA $135.26 2019-2023 Nobelactive
Gc America INC. $16.88 2021
Philips North America LLC $12.76 2023
Elevate Oral Care $10.96 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kyle King

$3,021.27

in general payments reported 2019-2025

Years
2019-2024
Top company
Ultradent Products INC

https://glasscript.com/doctor/1336894/kyle-king

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.